Neovii out-licenses Grafalon rights in China

Privately-held Swiss drug developer Neovii Pharmaceuticals has entered into an agreement with a unit of Shanghai Fosun Pharmaceutical (600196.SH, 02196.HK), granting the latter an exclusive license to develop and commercialize Neovii's Grafalon (rabbit anti-human T-lymphocyte globulin, ATLG) in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

Under the terms of the deal, Neovii is entitled to receive undisclosed upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon to Fosun Pharma. In addition, Fosun Pharma has the right to authorize its subsidiaries to specifically commercialize Grafalon.

Grafalon (formerly also known as "ATG-Fresenius S" and "ATG-F") was developed by Neovii and is used to improve patients' outcomes in transplantation medicine in more than 50 countries and, in selected countries, also to treat aplastic anemia. With more than 250,000 treated patients, 30 years of clinical experience and leadership position in many countries, Grafalon has transformed the way transplant teams manage the care of their patients and is uniquely addressing significant unmet needs.